Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$0.29
EPS est.
$0.23
EPS surprise
+26.09%
1-day move
-2.54%
Guardian Pharmacy Services reported an EPS of $0.29, which was below the expected $0.32. The stock reacted negatively, dropping 2.54%. The lack of revenue data and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.29 | $0.32 | +26.09% |
| Revenue | — | $366M | — |
No transcript is on record, and the analysis is based on numerical results only.
Guardian Pharmacy Services, Inc. operates in the health care sector, providing pharmacy services primarily to long-term care facilities. As the demand for specialized health care services continues to grow, Guardian plays a crucial role in ensuring that patients receive the medications they need in a timely and efficient manner.
Last quarter
In Q1 2026, Guardian Pharmacy Services reported an EPS of $0.29, exceeding expectations by 31.82%. However, the stock experienced a slight decline the following day.
Management promises and guidance
EPS beat streak
5Q
EPS beat rate
100%
Avg EPS surprise
+27.69%
Avg 1-day reaction
-0.38%
Analysts are cautiously optimistic about Guardian's upcoming earnings, expecting a solid performance based on previous results.
Bull case
If Guardian meets or exceeds the EPS estimate, it could reinforce investor confidence and lead to a positive stock reaction.
Bear case
Conversely, if the company fails to meet the EPS target, it may raise concerns about its growth trajectory and operational challenges.
Key metrics to watch
EPS
$0.32Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$366MTotal revenue reflects the company's ability to generate sales and is critical for assessing growth.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.32?
A beat on EPS could signal strong operational performance and boost investor sentiment.
Q2
What are the revenue projections for the upcoming quarter?
Revenue growth is crucial for assessing the company's market position and future prospects.
—
Est. EPS
$1.48
Est. Rev
$3.3B
Impl. Move
±16.9%
Why consensus could be wrong
The Street may underestimate Guardian's ability to leverage its operational efficiencies to drive higher margins this quarter.
Supporting evidence
The company has consistently beaten EPS estimates, indicating strong underlying performance.
Recent trends in the health care sector suggest increasing demand for specialized pharmacy services.
Options pricing suggests a significant move, indicating that investors are anticipating volatility.
Key risk
If revenue growth comes in below $363M, it could challenge the overall bullish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on whether Guardian can maintain its growth momentum in a competitive health care landscape.
Bull confirmed if
Achieving an EPS of $0.33 or higher would confirm the bull case.
Bear confirmed if
An EPS below $0.29 would support the bear case.
What the market is pricing for the move.
Implied Move
±11.48%
Historical Avg
±1.7%
The options market is pricing in a significant potential movement in the stock following the earnings report, suggesting heightened investor uncertainty.
Options are pricing ±11.5% while GRDN has averaged ±1.7% over the last 5 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
25.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Guardian beats expectations, history suggests the stock could rise by around +0.16%, confirming a positive outlook.
In line / cautious
If results are in line but management provides cautious commentary, the stock may experience muted movement.
Miss
Should the company miss expectations, history indicates a potential decline, with an average move of -1.77% following previous misses.
The lines on the call that would change the story.